Apnea del Sueño:
Diagnosis, Risks and Treatment

1. What Is Obstructive Apnea del Sueño

Obstructive sleep apnea (OSA) is a chronic sleep-related breathing disorder characterized by repetitive partial or complete collapse of the upper airway during sleep. Each episode — termed an apnea (complete cessation of airflow for ≥ 10 seconds) or hypopnea (≥ 30% reduction in airflow with ≥ 3% oxygen desaturation or an arousal) — leads to intermittent hypoxemia, hypercapnia and sleep fragmentation.

During normal sleep the pharyngeal dilator muscles, primarily the genioglossus, maintain airway patency. In patients with OSA, anatomical narrowing of the upper airway combined with reduced neuromuscular tone during sleep leads to repetitive airway collapse. The resulting negative intrathoracic pressure swings, cyclical oxygen desaturation and sympathetic surges produce a cascade of systemic effects that extend far beyond poor sleep quality.

OSA exists on a spectrum of severity. Central sleep apnea (CSA), by contrast, involves a failure of the brainstem respiratory drive rather than mechanical obstruction. Complex or treatment-emergent central apnea may also develop in patients with OSA once obstructive events are resolved with positive airway pressure. This article focuses primarily on OSA, which accounts for 84% of all sleep apnea diagnoses.

2. Risk Factors

OSA is a multifactorial condition with both anatomical and non-anatomical contributors. Understanding these risk factors is essential for screening and early identification:

• Obesity (BMI ≥ 30 kg/m²) — The single strongest modifiable risk factor. Fat deposition around the pharynx narrows the airway lumen. A 10% weight gain increases the odds of developing moderate-to-severe OSA by approximately six-fold (Peppard et al., JAMA, 2000).
• Male sex — Men are 2–3 times more likely to have OSA than premenopausal women, though this gap narrows substantially after menopause, suggesting a protective role of progesterone and estrogen on upper-airway tone.
• Age > 50 years — Prevalence increases with age due to progressive loss of pharyngeal muscle tone, increased soft-tissue deposition and changes in craniofacial structure.
• Craniofacial anatomy — Retrognathia (receding jaw), macroglossia (enlarged tongue), tonsillar hypertrophy and a low-lying soft palate all predispose to airway collapse. These factors explain why OSA also occurs in non-obese individuals.
• Neck circumference ≥ 43 cm (men) or ≥ 41 cm (women) — A practical bedside predictor that correlates with parapharyngeal fat deposition.
• Family history — First-degree relatives of OSA patients have a 2- to 4-fold increased risk, reflecting shared craniofacial morphology and body habitus.
• Alcohol, sedatives and opioids — These substances reduce pharyngeal muscle tone and blunt the arousal response, worsening both frequency and duration of obstructive events.
• Smoking — Current smokers have a 2.5-fold higher risk of OSA, likely due to upper-airway inflammation and edema.

3. Symptoms and Warning Signs

The clinical presentation of OSA is often insidious, developing over years. Patients frequently normalize their symptoms or attribute them to aging and stress. The hallmark triad includes loud habitual snoring, witnessed apneic episodes and excessive daytime sleepiness.

Nighttime Symptoms

• Loud, disruptive snoring — present in approximately 95% of OSA patients, often prompting bed-partner complaints before patient self-recognition.
• Witnessed apneas — the bed partner observes pauses in breathing followed by gasping or choking sounds as the patient arouses to reopen the airway.
• Nocturia — frequent nighttime urination (≥ 2 episodes) affects up to 50% of patients, driven by atrial natriuretic peptide release secondary to negative intrathoracic pressure swings.
• Restless sleep and nocturnal diaphoresis — repeated arousals cause body movements, positional changes and sweating.

Daytime Symptoms

• Excessive daytime sleepiness (EDS) — quantified by the Epworth Sleepiness Scale (ESS); scores > 10 are abnormal. Patients may fall asleep during meetings, while driving or during passive activities.
• Morning headaches — typically bilateral, dull, and resolving within 1–2 hours; caused by nocturnal CO₂ retention and cerebral vasodilation.
• Cognitive impairment — difficulty concentrating, memory deficits and reduced executive function. Chronic intermittent hypoxia damages hippocampal and prefrontal neurons.
• Mood disturbances — irritability, depression and anxiety are significantly more prevalent in untreated OSA patients.
• Decreased libido and erectile dysfunction — related to sympathetic overdrive, hormonal disruption and sleep fragmentation.

4. Diagnosis and Polysomnography

The gold standard for diagnosing OSA is in-laboratory polysomnography (PSG), also known as a Level 1 sleep study. During PSG, the patient sleeps overnight in a controlled environment while the following parameters are continuously monitored:

• Electroencephalography (EEG) — determines sleep stages (N1, N2, N3, REM) and identifies arousals.
• Electro-oculography (EOG) — detects eye movements to identify REM sleep.
• Electromyography (EMG) — chin and leg EMG to assess muscle tone and limb movements.
• Nasal pressure transducer and oronasal thermistor — measure airflow to identify apneas and hypopneas.
• Thoracoabdominal effort bands — distinguish obstructive from central events by demonstrating continued respiratory effort during airway obstruction.
• Pulse oximetry — records oxygen saturation (SpO₂) continuously throughout the night; identifies desaturation events.
• ECG — detects cardiac arrhythmias associated with apneic events (bradycardia–tachycardia pattern).
• Body position sensor — positional OSA (supine-predominant) can guide targeted therapy.

For patients with a high pre-test probability of moderate-to-severe OSA and no significant comorbidities, home sleep apnea testing (HSAT) — a Level 3 study — is an acceptable alternative. HSAT typically measures airflow, respiratory effort, and oxygen saturation but does not include EEG, limiting its ability to detect REM-related events or accurately quantify sleep time. A negative HSAT in a symptomatic patient should be followed by in-laboratory PSG.

5. Severity Classification (AHI)

The Apnea-Hypopnea Index (AHI) is the primary metric used to diagnose and classify the severity of OSA. The AHI is defined as the total number of apneas plus hypopneas per hour of sleep recorded during polysomnography. According to the American Academy of Medicina del Sueño (AASM), OSA is classified as follows:

While the AHI remains the cornerstone of severity assessment, it has important limitations. It does not account for the duration of respiratory events, the depth of oxygen desaturation, or the degree of sleep fragmentation. Two patients with an AHI of 25 may have vastly different clinical profiles depending on their oxygen desaturation patterns, arousal burden and symptom severity. Newer metrics such as the oxygen desaturation index (ODI), hypoxic burden and arousal index provide complementary information and are increasingly used in clinical practice and research.

6. CPAP Treatment

Continuous Positive Airway Pressure (CPAP) is the first-line treatment for moderate-to-severe OSA and remains the most extensively studied therapy. CPAP works by delivering a constant stream of pressurized air through a nasal or oronasal mask, creating a pneumatic splint that prevents upper-airway collapse during sleep.

The optimal CPAP pressure is typically determined during a titration polysomnography, in which the pressure is incrementally increased until apneas, hypopneas, snoring and desaturations are eliminated in all sleep stages and body positions. Most patients require pressures between 6 and 14 cmH₂O. Auto-titrating CPAP (APAP) devices, which adjust pressure breath-by-breath based on real-time airflow analysis, have become increasingly popular and are non-inferior to fixed-pressure CPAP for most patients.

Benefits of CPAP Therapy

• Elimination of apneic events — AHI is typically reduced to < 5 events/hour with adequate pressure and compliance.
• Resolution of daytime sleepiness — ESS scores normalize within 2–4 weeks of consistent use; driving risk decreases significantly.
• Blood pressure reduction — meta-analyses demonstrate a mean reduction of 2–3 mmHg in systolic and diastolic blood pressure; the effect is greater in patients with resistant hypertension and those using CPAP for > 4 hours/night.
• Cardiovascular protection — observational data suggest that long-term CPAP use is associated with reduced risk of fatal and non-fatal cardiovascular events, though the randomized SAVE trial showed no benefit with suboptimal adherence (mean 3.3 h/night).
• Improved glycemic control — CPAP use reduces insulin resistance and improves HbA1c in patients with OSA and type 2 diabetes.
• Enhanced cognitive function and mood — memory, attention and depressive symptoms improve with consistent CPAP use.

Adherence Challenges

CPAP adherence is the Achilles' heel of OSA management. Studies consistently show that 30–50% of patients fail to meet the minimum adherence threshold of 4 hours/night on 70% of nights — the standard used by most insurance and regulatory bodies. The most commonly reported barriers include mask discomfort, nasal congestion, claustrophobia, aerophagia (air swallowing) and noise. Strategies to improve adherence include proper mask fitting, heated humidification, ramp-up pressure settings, cognitive behavioral therapy for CPAP adherence (CBT-CPAP) and regular telemedicine follow-up with data review.

7. Alternatives to CPAP

For patients who cannot tolerate CPAP or who have mild-to-moderate OSA, several alternative therapies are available:

• Mandibular Advancement Devices (MADs) — custom-fitted oral appliances that protrude the mandible forward by 6–10 mm, increasing the retropalatal and retroglossal airway space. They are recommended by the AASM as first-line therapy for mild OSA and as second-line for moderate-to-severe OSA with CPAP intolerance. AHI reduction of 50–70% is typical.
• Positional therapy — for patients with supine-predominant OSA (defined as supine AHI ≥ 2× non-supine AHI), avoiding the supine position using positional devices, tennis-ball techniques or specialized pillows can significantly reduce the AHI. Newer vibrotactile positional devices show better long-term adherence.
• Hypoglossal nerve stimulation (Inspire therapy) — an implantable neurostimulator that activates the genioglossus muscle synchronously with inspiration, preventing airway collapse. Approved for patients with moderate-to-severe OSA (AHI 15–65) who have failed CPAP and do not have concentric palatal collapse on drug-induced sleep endoscopy (DISE). The STAR trial showed a 68% reduction in AHI at 12 months.
• Weight loss — a 10–15% reduction in body weight can reduce the AHI by 50% or more. Bariatric surgery achieves the greatest and most sustained weight loss and may effectively cure OSA in select patients with severe obesity. GLP-1 receptor agonists (semaglutide, tirzepatide) are emerging as pharmacological adjuncts for weight management in OSA patients.
• Maxillomandibular advancement (MMA) surgery — orthognathic surgery that advances both the maxilla and mandible by 10–12 mm, permanently enlarging the skeletal framework of the upper airway. Success rates exceed 85% in carefully selected patients, and it is considered the most effective surgical option for OSA.
• Uvulopalatopharyngoplasty (UPPP) — removal of redundant soft palate tissue, uvula and tonsils. Historically the most common OSA surgery, but with inconsistent results (success rate ~40–50%) due to failure to address all levels of obstruction.

8. Cardiovascular Consequences

The relationship between OSA and cardiovascular disease is one of the most important areas of sleep medicine research. OSA acts as an independent risk factor for a wide range of cardiovascular conditions through several interconnected pathophysiological mechanisms:

• Intermittent hypoxia — cyclical desaturation-reoxygenation generates reactive oxygen species (ROS), triggering oxidative stress, endothelial dysfunction and systemic inflammation (elevated CRP, TNF-α, IL-6).
• Sympathetic nervous system activation — repeated arousals and hypoxia cause sustained sympathetic overdrive, elevated catecholamines and loss of normal nocturnal blood pressure dipping (non-dipping pattern).
• Intrathoracic pressure swings — exaggerated negative pressures during obstructed inspiratory efforts increase left ventricular afterload and atrial stretch, promoting atrial fibrillation and heart failure.
• Metabolic dysregulation — OSA independently contributes to insulin resistance, dyslipidemia and visceral adiposity, creating a synergistic cycle with obesity.

Specific Cardiovascular Associations

Systemic hypertension is the most robustly established cardiovascular consequence. The Wisconsin Sleep Cohort Study demonstrated a dose-response relationship: compared to subjects with an AHI of 0, those with an AHI ≥ 15 had a 2.89-fold increased odds of developing hypertension over 4 years, independent of confounders. OSA is present in 30–50% of patients with resistant hypertension (uncontrolled BP despite ≥ 3 antihypertensive agents).

Atrial fibrillation (AF) is 2–4 times more common in patients with OSA. Untreated OSA is associated with a 25% higher recurrence rate of AF after cardioversion or catheter ablation. CPAP treatment reduces this recurrence risk.

Heart failure — OSA contributes to both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). The cyclical negative intrathoracic pressure increases left ventricular transmural pressure and afterload. Prevalence of sleep-disordered breathing in heart failure patients exceeds 50%.

Stroke — severe OSA (AHI ≥ 30) approximately doubles the risk of ischemic stroke. Post-stroke patients with untreated OSA have worse functional recovery and higher mortality. Screening for OSA should be considered in all stroke patients.

Sudden cardiac death — while sudden cardiac death in the general population peaks between 6 AM and noon, patients with OSA show a reversed pattern with peak incidence between midnight and 6 AM, coinciding with the period of maximal sleep-disordered breathing. The risk of nocturnal sudden death increases proportionally with OSA severity.